Kathy Tran

Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia

Geoffrey L. Uy, Ibrahim Aldoss, Matthew C. Foster et al. · Blood · 2020 · 322 citations · Full text

Medicine, Hematology, Oncology +13

Preliminary Results of a Phase 1 Study of Flotetuzumab, a CD123 x CD3 Bispecific Dart® Protein, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Geoffrey L. Uy, John E. Godwin, Michael P. Rettig et al. · Blood · 2017 · 62 citations

Medicine, Hematology, Oncology +17

Phase 1 Cohort Expansion of Flotetuzumab, a CD123×CD3 Bispecific Dart® Protein in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Geoffrey L. Uy, Michael P. Rettig, Norbert Vey et al. · Blood · 2018 · 39 citations

Medicine, Oncology, Pharmacology +17

Flotetuzumab, an Investigational CD123 x CD3 Bispecific Dart® Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) Patients

Geoffrey L. Uy, Ibrahim Aldoss, Matthew C. Foster et al. · Blood · 2019 · 16 citations

Medicine, Oncology, Pharmacology +16

Flotetuzumab As Salvage Therapy for Primary Induction Failure and Early Relapse Acute Myeloid Leukemia

Ibrahim Aldoss, Geoffrey L. Uy, Norbert Vey et al. · Blood · 2020 · 15 citations

Medicine, Hematology, Oncology +12